Publications

  • Freuchet, A. A. Salama, S. Remy, C. Guillonneau* and I. Anegon*.. IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases. 2021. J. Leuk. Biol. in press.

  • Amini, L, J. Greig, M. Schmueck-Henneresse, H-D. Volk, S. Bézie, P. Reinke, C. Guillonneau*, D. L. Wagner*, I. Anegon*. Super-Treg: towards a new era of adoptive Treg therapy enabled by genetic modifications. 2021. Front. Immunol. in press.

  • Boucault, M-D. Lopez Robles, A. Thiolat, S. Bézie, M. Schmueck-Henneresse, C. Braudeau, N. Vimond, A. Freuchet, E. Austrusseau, F. Charlotte, R. Redjoul, F. Beckerich, M. Leclerc, E. Piaggio, R. Josien, H-D. Volk, S. Maury, J. L Cohen, I. Anegon* and C. Guillonneau*. Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. 2020. Blood Adv. 4. 2501-2515. Read

  • Bézie, C., A. Freuchet, C. Sérazin, A. Salama, S. Usal, N. Vimond, I. Anegon* and C. Guillonneau*. IL-34 actions on FOXP3+ Tregs and CD14+ monocytes control human graft rejection. 2020. Front. Immunol. 11:1496. Read
  • Bézie S., B. Charreau, N. Vimond, J. Lasselin, N. Gérard, V. Nerrière-Daguin, F. Bellier-Waast, F. Duteille, I. Anegon* and C. Guillonneau*. Human CD8+ Tregs expressing a MHC-specific chimeric antigen receptor display enhanced suppression of human skin rejection and GVHD in NSG mice. 2019. Blood Adv. 3:3522. Read
  • Ouisse L-H., S. Remy, A. Lafoux, T. Larcher, L. Tesson, V. Chenouard, C. Guillonneau, L. Brusselle, N. Vimond, K. Rouger, Y. Péréon, A. Chenouard, C. Gras-Le Guen, C. Braudeau, R. Josien, C. Huchet, I. Anegon. Immunophenotype of a rat model of Duchenne’s disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment. 2019. Front. Immunol. 10:2131. Read
  • Bézie S., I. Anegon* and C. Guillonneau*. Advances on CD8+ Tregs and their potential in transplantation. 2018. Transplantation. 102 (9), 1467. Read
  • Bézie S., D. Meistermann, L. Boucault, S. Kilens, J. Zoppi, E. Autrusseau, A. Donnart, V. Nerrière-Daguin, F. Bellier-Waast, E. Charpentier, F. Duteille, L. David, I. Anegon* and C. Guillonneau*. Ex vivo expanded human non-cytotoxic CD8+CD45RClow/− Tregs efficiently delay skin graft rejection and GVHD in humanized mice. 2018. Frontiers in Immunology. 8:2014. Read
  • Guillonneau C*., S. Bézie, I. Anegon*. Immunoregulatory properties of the cytokine IL-34. 2017. Cellular and Molecular Life Science. 74: :2569. Read
  • Bézie S., L. Boucault, E. Autrusseau, S. Kilens, D. Meistermann, B. Martinet, V. Daguin, A. Donnart, E. Charpentier, L. David, I. Anegon* and C. Guillonneau*. Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells. 2017. J. Clin. Invest. Insight. 9;2(3):e90088. Read
  • Bézie, S., Picarda, E., Ossart, J., Tesson, L., Usal, C., Renaudin, K., Anegon, I.*, and Guillonneau, C*. Interleukin-34, a new Treg-specific cytokine mediator of transplant tolerance. 2015. J. Clin. Invest., 125(10):3952. Read
  • Picarda E., S. Bézie, V. Venturi, K. Echasserieau, E. Merieau, A. Delhumeau, K. Renaudin, S. Brouard, K. Bernardeau, I. Anegon and C. Guillonneau. Donor MHC-derived peptide recognized by TCR biased-CD8+ Tregs suppresses organ rejection. 2014. J. Clin. Invest, 124:2497-. Read
  • Li X-L., S. Ménoret, S. Bezie, L. Caron, D. Chabannes, M. Hill, F. Halary, M. Angin, M. Heslan, C. Usal, L. Liang, C. Guillonneau, B. Le Mauff, M-C. Cuturi, R. Josien, I. Anegon. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. 2010. J. Immunol. 185:823. Read
  • Guillonneau1 C., C. Séveno1, A-S. Dugast, X-L. Li, K. Renaudin, F. Haspot, C. Usal, J. Véziers, I. Anegon* and B. Vanhove*. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. 2007. J. Immunol. 179: 8164. Read
  • Guillonneau C., V. Aubry, K. Renaudin, C. Séveno, C. Usal, K. Tezuka, I. Anegon. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L costimulation blockade. 2007. Transplantation. 80:255. Read
  • Guillonneau C., M. Hill, F-X. Hubert, E. Chiffoleau, C. Hervé, X-L Li, M. Heslan, C. Usal, L. Tesson, S. Ménoret, A. Saoudi, B. Le Mauff, R. Josien, M. C. Cuturi and I. Anegon. CD40Ig treatment results in allograft acceptance mediated by CD8+CD45RClow T cells, IFNgamma and indoleamine 2,3 dioxygenase. 2007. J. Clin. Invest. 117 :1096. Read